DGX - Quest Diagnostics Incorporated

NYSE - NYSE Delayed Price. Currency in USD
122.61
+4.17 (+3.52%)
At close: 4:00PM EDT

122.61 0.00 (0.00%)
After hours: 5:09PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close118.44
Open120.01
Bid120.00 x 900
Ask122.61 x 1300
Day's Range119.71 - 123.39
52 Week Range73.02 - 125.00
Volume2,140,907
Avg. Volume2,248,282
Market Cap16.397B
Beta (5Y Monthly)1.37
PE Ratio (TTM)21.10
EPS (TTM)5.81
Earnings DateJul 21, 2020 - Jul 27, 2020
Forward Dividend & Yield2.24 (1.89%)
Ex-Dividend DateJul 07, 2020
1y Target Est122.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-9% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Have Never Been More Bullish On Quest Diagnostics Incorporated (DGX)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Quest Diagnostics Incorporated (DGX)

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Quest’s Covid-19 Self-Collection Test Kit Gets FDA Nod For Emergency Use
    SmarterAnalyst

    Quest’s Covid-19 Self-Collection Test Kit Gets FDA Nod For Emergency Use

    Quest Diagnostics Inc. (DGX) said it has received emergency use authorization (EUA) for its self-collection Covid-19 test kit from the U.S. Food and Drug Administration (FDA).The company expects to have more than 500,000 kits available by the end of June, with plans to make additional kits on an ongoing basis. The kit enables individuals to self-collect a nasal specimen sample using a swab at home or in a healthcare setting when requested by a healthcare provider."COVID-19 molecular diagnostic testing has been constrained partly by limited supplies of swabs and trained healthcare professionals to do the specimen collection," said Steve Rusckowski, Quest’s Chairman, CEO and President. "The self-collection kit enables an individual to self-collect at home, and the process is far less invasive and uncomfortable than many traditional methods."The self-collection kit can also be used on children supervised by an adult as well as adults. The collected specimens are shipped overnight via FedEx to labs and can be tested with Quest’s SARS-CoV-2 RT-PCR test that received EUA in March, the company said. It plans to make the self-collection kits available for healthcare providers for patient care and healthcare workers as well as for return-to-work testing programs.The diagnostics company added that it already tested specimens using a similar collection method in real-world settings in drive-thru facilities and other onsite Covid-19 testing sites across the U.S.Since the beginning of April, Quest Diagnostics’ shares have almost doubled and are trading at $118.28 as of Friday’s close.Despite the recent rally, five-star analyst David S Macdonald at SunTrust Robinson on May 21 raised the stock’s price target to $130 (9.9% upside potential) from $110, while maintaining a Hold rating on the stock.Wall Street analysts take a cautiously optimistic stance on the stock. The Moderate Buy consensus is made up of 8 Holds, 5 Buys and 1 Sell. The $115.36 average price target now implies 2.5% downside potential for the shares in the coming 12 months. (See Quest Diagnostics stock analysis on TipRanks). Related News: Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11% Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses; Top Analyst Ramps Up PT To $61 More recent articles from Smarter Analyst: * Philips Gets FDA Emergency Use Nod For Monitors, Displays During Covid-19 Pandemic * National Instruments To Buy OptimalPlus In $365 Million Deal * Free Version of WWE Network Now Available for Fans * Bristol Myers Reveals Positive Results For Ulcerative Colitis Pivotal Trial

  • Quest Diagnostics to Speak at the Jefferies Virtual Healthcare Conference
    PR Newswire

    Quest Diagnostics to Speak at the Jefferies Virtual Healthcare Conference

    Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Virtual Healthcare Conference. Mark Guinan, Executive Vice President and CFO and Jim Davis, Executive Vice President, General Diagnostics, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence, and the company's current perspective on the impact of the COVID-19 pandemic. The presentation is scheduled for Wednesday, June 3, 2020 at 1:30 p.m. Eastern Time.

  • Home State Health and Quest Diagnostics Team Up to Increase Access to COVID-19 Testing in Underserved Communities
    PR Newswire

    Home State Health and Quest Diagnostics Team Up to Increase Access to COVID-19 Testing in Underserved Communities

    Home State Health announced a collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to increase access to real-time reverse transcription polymerase chain reaction (rRT-PCR) COVID-19 testing in critical areas of need in St. Louis. Through this collaboration, Home State will facilitate the distribution of up to 1,000 Quest COVID-19 test kits each week to Affinia Healthcare and People's Health Centers, Federally Qualified Health Centers (FQHCs).

  • Coronavirus update: U.S. marks grim milestone as Trump preps executive order on social-media companies
    MarketWatch

    Coronavirus update: U.S. marks grim milestone as Trump preps executive order on social-media companies

    The U.S. death toll from the coronavirus that causes COVID-19 rose above 101,000 on Thursday, one day after it exceeded the 100,000 level, a grim marker for the nation with the highest number of cases and deaths in the world.

  • MarketWatch

    Quest's shares rise as FDA authorizes its at-home COVID-19 test

    Shares of Quest Diagnostics Inc. gained 2.7% in trading on Thursday after the company said the Food and Drug Administration had granted emergency use authorization to the company's first at-home COVID-19 test kit. Quest has received EUAs for several tests during the coronavirus pandemic, including for its diagnostic and antibody tests. The at-home test allows adults or their children to gather a nasal sample using a swab at a home and then send out the specimen for shipping using FedEx Corp. at the discretion of a health care provider. Quest said it has already tracked individuals collecting their own specimens at drive-through testing sites, including at Walmart Inc. locations. That's something that Quest CEO Steve Rusckowski mentioned on an earnings call in April. Quest's stock is up 11.6% year-to-date, while the S&P 500 is down 6.0%.

  • FDA Authorizes Quest Diagnostics COVID-19 Nasal Specimen Self-Collection Kit for Emergency Use
    PR Newswire

    FDA Authorizes Quest Diagnostics COVID-19 Nasal Specimen Self-Collection Kit for Emergency Use

    Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Quest Diagnostics Self-collection Kit for COVID-19 (self-collection kit). The self-collection kit is for individuals to self-collect a nasal specimen at home or in a healthcare setting when determined to be appropriate by a healthcare provider.

  • Coronavirus update: Novartis enters vaccine race as reopenings, testing efforts ramp up
    Yahoo Finance

    Coronavirus update: Novartis enters vaccine race as reopenings, testing efforts ramp up

    Pharmaceutical companies on Thursday continued their pursuit of a breakthrough in the fight against the coronavirus pandemic.

  • Coronavirus latest: Wednesday, May 27
    Yahoo Finance Video

    Coronavirus latest: Wednesday, May 27

    On Wednesday, Novavax announced that it would be acquiring Praha Vaccines as a way to expand its coronavirus vaccine manufacturing capacity. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.

  • Quest Diagnostics rolls out return-to-work services
    Yahoo Finance Video

    Quest Diagnostics rolls out return-to-work services

    Quest Diagnostics Chief Medical Officer Jay Wohlgemuth joins Yahoo Finance’s Anjalee Khemlani and Akiko Fujita to discuss Quest Diagnostics' move to roll out return-to-work services.

  • Quest Diagnostics launches workforce testing for coronavirus
    Reuters

    Quest Diagnostics launches workforce testing for coronavirus

    May 27 (Reuters) - Quest Diagnostics Inc on Wednesday launched services to support large-scale testing for the new coronavirus, as companies look to bring employees back to offices safely. The company said it was scaling up its COVID-19 lab operations to accommodate expected demand.

  • Quest Diagnostics Launches COVID-19 Workforce Testing Services to Help Guide Organizations in Fostering Safer Workplaces as Employees Return to Work
    PR Newswire

    Quest Diagnostics Launches COVID-19 Workforce Testing Services to Help Guide Organizations in Fostering Safer Workplaces as Employees Return to Work

    Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today launched a new suite of Return to Work services built around large-scale workforce COVID-19 testing. The services are designed to help organizations access and act on COVID-19 laboratory insights in order to foster safer workplace environments for their employees as the nation begins to restart the U.S. economy.

  • Insurers eye payment 'recalibration' as coronavirus fuels shift to telehealth, testing
    Yahoo Finance

    Insurers eye payment 'recalibration' as coronavirus fuels shift to telehealth, testing

    “There are a number of questions given the shock that happened to the system,” a Blue Cross Blue Shield Association executive told Yahoo Finance in a recent interview.

  • Arkansas Health & Wellness, Arkansas Total Care and Quest Diagnostics Team Up to Increase Access to COVID-19 Testing in Underserved Communities
    PR Newswire

    Arkansas Health & Wellness, Arkansas Total Care and Quest Diagnostics Team Up to Increase Access to COVID-19 Testing in Underserved Communities

    Arkansas Health & Wellness and Arkansas Total Care announced today a collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to increase access to real-time reverse transcription polymerase chain reaction (rRT-PCR) COVID-19 testing in critical areas of need in Arkansas. Through this collaboration, Arkansas Health & Wellness and Arkansas Total Care will facilitate the distribution of approximately 1,000 Quest COVID-19 test kits each week to Community Health Centers of Arkansas. The FQHCs will conduct testing as part of a broader initiative to test persons who are symptomatic and asymptomatic in our underserved communities.

  • Quest Diagnostics Declares Quarterly Cash Dividend
    PR Newswire

    Quest Diagnostics Declares Quarterly Cash Dividend

    Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on July 22, 2020 to shareholders of record of Quest Diagnostics common stock on July 8, 2020.

  • Top 5 Buys of Jeremy Grantham's GMO in the 1st Quarter
    GuruFocus.com

    Top 5 Buys of Jeremy Grantham's GMO in the 1st Quarter

    Firm’s top buy is in Buffett’s favorite drink, Coca-Cola Continue reading...

  • Coronavirus Vaccine Progress Accelerates
    Yahoo Finance

    Coronavirus Vaccine Progress Accelerates

    Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

  • Morgan Stanley: 2 Stocks That Could Surge Over 25%
    TipRanks

    Morgan Stanley: 2 Stocks That Could Surge Over 25%

    COVID-19 has left the U.S. economy reeling, yet Wall Street is pushing forward. Unemployment has reached alarming levels, with the loss of 20.5 million jobs in April bringing the U.S. unemployment rate to 14.7%, but the S&P 500 has staged somewhat of a recovery. While the index dipped Tuesday as investors weighed reopening efforts against fears of a second wave of infections, it has gained about 30% since hitting lows in March.So, what’s driving this stock market disconnect? Mike Wilson, Morgan Stanley's chief U.S. equity strategist, argues that investors are betting on a future recovery, with these bets being primarily fueled by concrete actions rather than the unknown. Additionally, he points out that market watchers believe the rebound will be “V-shaped”, the most ambitious form of an economic recovery.“Our client conversations have changed dramatically over the past month, shifting from whether we will have a re-test of the March lows to what does the shape of a recovery look like. Our view is that we will see a sustainable V-shaped recovery,” Wilson commented. He added, “... primarily because history tells us this is the way it always looks and feels in a recession — a highly uncertain recovery path, pessimistic investors, and volatile asset markets reacting to daily updates about the exogenous shock that got us here in the first place.”Taking Wilson’s statements to heart, we used TipRanks’ database to take a closer look at two stocks that have received Morgan Stanley's stamp of approval. TipRanks revealed that both Buy-rated names have amassed support from other analysts and boast over 25% upside potential. Zentalis Pharmaceuticals (ZNTL)Focused on the creation of differentiated small molecule treatments that target biological pathways of cancer, Zentalis believes it has developed an integrated approach that will allow it to overcome the limitations of current cancer therapeutics. Morgan Stanley highlights the speed of its pipeline advancement and the quality of its technology as making this company a standout in a crowded space.Representing the firm, five-star analyst Matthew Harrison cites ZNTL’s four INDs in a short period of time as proof of its development capabilities. “Small molecule targeted oncology is an attractive area for investment as initial results on efficacy and safety can quickly de-risk an asset and lead to fast approvals. Management has built a top-notch, differentiated chemistry group which has allowed Zentalis to quickly build a large pipeline against key targets,” he explained.Looking specifically at its lead asset, ZN-c5, a small molecule selective estrogen receptor degrader (SERD) designed for use in breast cancer, Harrison points out that it has already demonstrated clinically and preclinically low levels of major side effects as well as robust efficacy. This is important because while oral SERDs could be used across multiple stages of breast cancer and are more convenient than injectables, other oral SERDs in development have caused side effects like rash, diarrhea and vomiting. Based on all of this, the analyst thinks the opportunity for ZN-c5 could land in the billions.The good news doesn’t stop there. Harrison stated, “Importantly, the rest of the pipeline is robust, offering additional compelling targets.” In particular, he estimates that its Wee1 (ZN-c3) candidate could see peak sales hit $1 billion. When it comes to Bcl-2 (ZN-d5), Harrison argues that this therapy is a de-risked target with only one key competitor, with it possibly allowing ZNTL to differentiate itself. It should also be noted that the company has a third generation EGFR inhibitor that could be used alongside its SERD.It should come as no surprise, then, that Harrison joined the bulls. To kick off his coverage, he put an Overweight call and $45 price target on the stock. Should this target be met, a twelve-month gain of 26% could be in store. (To watch Harrison’s track record, click here) Does the rest of the Street agree with Harrison? With 100% Street support, or 4 Buy ratings to be exact, the consensus is unanimous: ZNTL is a Strong Buy. In addition, the $43.67 average price target implies 23% upside potential. (See Zentalis stock analysis on TipRanks)Quest Diagnostics Inc. (DGX)When it comes to laboratory diagnostic information services company Quest Diagnostics, Morgan Stanley has had a change of heart. Back in March, the firm downgraded the stock due to the overwhelming headwinds it thought couldn’t be offset by COVID-19 testing, but now it’s singing a different tune.Weighing in on DGX for the firm, five-star analyst Ricky Goldwasser argues that expanded testing guidelines as well as new market opportunities bode well for the company. Even though Wall Street has been laser-focused on the opportunity related to serology testing recently, based on Goldwasser’s analysis, the COVID-19 diagnostic testing opportunity could be two times larger if testing is added as part of a pre-elective procedure routine. She also points out that since March, supply shortages have limited COVID-19 testing, which in turn has spurred restrictive testing guidelines in an effort to save supplies.Expounding on this, Goldwasser stated, “Over time, as supplies become more available, testing guidelines are starting to expand. We expect Quest Diagnostics to meaningfully benefit from the market evolution to phase II of the testing paradigm and out of the four walls of the hospital. Our analysis suggests COVID-19 diagnostics could translate to ~689 million revenue opportunity and $372 million in EBIT through 2021.”That’s not to say serology testing isn’t important for DGX, with Goldwasser noting it’s a “critical component in reopening business.” She added, “Employers who are developing their return to work programs are working with the national labs to create testing programs. While the opportunity is going to be split among other supply chain participants (drug retail chains included), we estimate this as a $335 million revenue opportunity for Quest through the fall of 2020 helping to offset some of the declines in core testing.”All of the above prompted Goldwasser to upgrade her rating from Equal-weight to Overweight. On top of this, she bumped up the price target from $95 to $139. This new target suggests shares could surge 29% in the next twelve months. (To watch Goldwasser’s track record, click here) Looking at the consensus breakdown, DGX has been assigned 5 Buys, 8 Holds and 1 Sell in the last three months. As a result, it earns a Moderate Buy consensus rating. At $111.43, the average price target puts the upside potential at a modest 3.4%. (See Quest Diagnostics stock analysis on TipRanks)Read more: * 3 Biotech Stocks Under $4 That Could Surge Over 50% * 3 “Strong Buy” Penny Stocks With Triple-Digit Upside

  • Quest Diagnostics Prices $550 Million of Senior Notes
    PR Newswire

    Quest Diagnostics Prices $550 Million of Senior Notes

    Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $550 million aggregate principal amount of its 2.800% senior notes due 2031 under Quest Diagnostics' shelf registration statement.

  • Moody's

    Quest Diagnostics Incorporated -- Moody's assigns Baa2 rating to Quest Diagnostics' notes offering

    Moody's Investors Service, ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating.

  • Ortho Clinical Diagnostics and Quest Diagnostics to Broaden Availability of COVID-19 Antibody Testing
    CNW Group

    Ortho Clinical Diagnostics and Quest Diagnostics to Broaden Availability of COVID-19 Antibody Testing

    Ortho Clinical Diagnostics and Quest Diagnostics to Broaden Availability of COVID-19 Antibody Testing

  • Better Coronavirus Stock: Quest Diagnostics or LabCorp?
    Motley Fool

    Better Coronavirus Stock: Quest Diagnostics or LabCorp?

    No matter what happens, though, testing for COVID-19 will be important. Two of the largest diagnostics testing companies in the world, Quest Diagnostics (NYSE: DGX) and LabCorp (NYSE: LH), have stepped up in a major way to provide COVID-19 testing. Quest Diagnostics launched nationwide COVID-19 testing services in March.

  • Quest Diagnostics’ History of Acquisitions is Paying Off
    Motley Fool

    Quest Diagnostics’ History of Acquisitions is Paying Off

    The company’s powerful regional network of laboratories and its ever-expanding set of diagnostic products are locking in its long term growth potential.